Mark K. Oki - 17 Jan 2022 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role
Chief Financial Officer
Signature
/s/ Josh Disbrow as attorney-in-fact for Mark K. Oki
Issuer symbol
AYTU
Transactions as of
17 Jan 2022
Net transactions value
$0
Form type
4
Filing time
19 Jan 2022, 10:42:33 UTC
Next filing
28 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AYTU Common Shares Award $0 +100,000 $0.000000 100,000 17 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted share grant. One-third of the restricted shares shall vest on January 17, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/12th of the original grant, with full vesting on January 17, 2025.